Clinical Trial

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT/PI3K/PTEN pathway alterations.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2025-07-30; most recent amendment 2026-05-20.
Status change: Not Yet Recruiting → Recruiting 2025-08-07
Trial Details
NCT Number NCT07109726
Lead Sponsor Terremoto Biosciences Inc.
Conditions Breast Cancer, Endometrial Cancer, Ovarian Cancer, Lung Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma, Solid Tumor, Cervical Cancer
Enrollment 205 participants
Start Date 2025-09-23
Primary Completion 2028-12-30 (estimated)
Study Completion 2029-02-28 (estimated)
Updated on ClinicalTrials.gov 2026-05-22